IP Library Granted Patent US 10,207,110
Granted Patent B1
US 10,207,110 · App. 15/293,021 · Granted Feb 19, 2019

Devices and methods for treatment of heart failure via electrical modulation of a splanchnic nerve

Inventors: Mark Gelfand (New York, NY); Tamara Colette Baynham (Bowie, MD); Howard Levin (Teaneck, NJ)
Assignee: Axon Therapies, Inc.
A61N1/36114A61B5/4848A61N1/0556A61N1/3627A61N1/36135
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,207,110
App. No.
15/293,021
Granted
Feb 19, 2019
Kind
B1
Abstract

Disclosed herein is a device, and method for treating heart failure by electrically modulating a splanchnic nerve with an implantable device.

Claims (16)

1. A method of treating heart failure or symptoms associated with heart failure in a human patient, comprising:

in a patient with heart failure or symptoms associated with heart failure;

thoracoscopically accessing at least one greater splanchnic nerve; and

affixing an implantable neuromodulation device with a tripolar nerve cuff to the at least one greater splanchnic nerve, the tripolar nerve cuff including first, second and third electrodes axially spaced from at least one of the other electrodes, and the axial spacing between adjacent electrodes is 1 to 2 mm the implantable neuromodulation device further comprising a pulse generator, a detection member for detecting at least one physiological parameter, and at least one lead for delivering stimulus to the at least one greater splanchnic nerve through the tripolar nerve cuff,

wherein the delivered stimulus has a frequency of at least 6 kHz and an amplitude of at least 10 mA to cause a reversible blockage to conduction along the at least one greater splanchnic nerve.

2. The method of claim 1 , wherein the at least one greater splanchnic nerve is at least one of a left greater splanchnic nerve and a right greater splanchnic nerve.

3. The method of claim 1 , wherein thoracoscopically accessing is selected from the group consisting of transthoracic, transabdominal, percutaneous, access or any combination thereof.

4. The method of claim 1 , wherein the patient has diastolic heart failure or symptoms associated with diastolic heart failure.

5. The method of claim 1 , wherein said implantable neuromodulation device further comprises a cardiac pulse generator configured to generate electrical stimulation pulses for delivery by one or more cardiac leads.

6. The method of claim 1 , wherein the implantable neuromodulation device further comprises a programmable microcontroller configured to control at least one operation of the implantable neuromodulation device.

7. The method of claim 6 , wherein the programmable microcontroller controls at least one operation chosen from the group consisting of logic processing, application of nerve blocking therapy, physiological monitoring, electroneurogram sensing, cardiac sensing, and any combination thereof.

8. The method of claim 7 , wherein the method of treatment further comprises an exercise detection step whereby the application of nerve blocking therapy may be arrested by the detection of exercise.

9. The method of claim 1 , wherein the detection member for detecting at least one physiological parameter is configured to detect a physiological parameter selected from the group consisting of orientation, acceleration, cardiac preload, cardiac afterload, cardiac output, stroke volume, blood pressure, venous congestion, pulmonary congestion, sense of dyspnea, heartrate, end-diastolic volume, end-systolic volume, venous return or any combination thereof.

10. The method of claim 9 , further comprising monitoring the physiological parameters to determine a therapy effectiveness.

11. The method of claim 9 , further comprising selecting at least one physiological parameter to be transmitted from the implantable neuromodulation device to an external programmer or display.

12. The method of claim 1 , further comprising deflating the lung proximate to the at least one greater splanchnic nerve.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 1, 2025
From: AXON THERAPIES, INC.
To: AXON (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
Reel/Frame 071149/0588 →
PATENT ASSIGNMENT AGREEMENT Recorded Nov 13, 2024
From: AXON (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC
To: AXON VASCULAR, INC.
Reel/Frame 069353/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2019
From: GELFAND, MARK; BAYNHAM, TAMARA COLETTE; LEVIN, HOWARD
To: AXON THERAPIES, INC.
Reel/Frame 047880/0864 →
Continuity (1)
Provisional Application 62240864 · Oct 13, 2015
Cited By (10)
US 12,349,966 US 12,408,974 US 12,420,098 US 12,478,806 US 12,521,559 US 12,539,167 US 12,551,707 US 12,569,690 US 12,661,177 US 12,708,433